SHSE:688796 (China)
Â
Ordinary Shares- Class A
Â¥
134.13
-3.87 (-2.8%)
Sep 22
Business Description
Biocytogen Pharmaceuticals (Beijing) Co Ltd
SIC : 8731
ISIN : CNE100007D74
Share Class Description:
SHSE:688796: Ordinary Shares- Class ATotal Employee Number:
1,443Compare
Compare
Traded in other countries / regions
02315.Hong Kong688796.ChinaI54.Germany IPO Date
2025-12-10Description
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a China-based biotechnology company that operates two main businesses: biopharmaceutical research and development, and preclinical research services. Its drug pipeline includes antibody therapeutics developed through its proprietary RenMab and related genetically engineered mouse platforms, which produce fully human antibodies for targets such as CD40, CTLA-4, and others in immuno-oncology. The company also provides preclinical models, gene-editing services, and antibody discovery services to pharmaceutical and biotechnology customers worldwide, generating revenue through research service fees, licensing arrangements, and collaboration agreements. Its animal model business supplies genetically modified mice and related products to academic and industry researchers. Biocytogen is headquartered in Beijing, China, and has expanded internationally, including operations in the United States and Europe, serving global pharmaceutical partners across oncology and other therapeutic areas.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.45 | |||||
Equity-to-Asset | 0.67 | |||||
Debt-to-Equity | 0.29 | |||||
Debt-to-EBITDA | 1.57 | |||||
Interest Coverage | 6.95 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 19.15 | |||||
Beneish M-Score | -2.5 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 34.5 | |||||
3-Year Book Growth Rate | 19.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 70.23 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 36.07 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 79.84 | |||||
9-Day RSI | 67.32 | |||||
14-Day RSI | 60.78 | |||||
3-1 Month Momentum % | 42.58 | |||||
6-1 Month Momentum % | 73.44 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.42 | |||||
Quick Ratio | 2.98 | |||||
Cash Ratio | 2.02 | |||||
Days Inventory | 170.5 | |||||
Days Sales Outstanding | 57.66 | |||||
Days Payable | 116.31 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.6 | |||||
Shareholder Yield % | -0.14 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 78.3 | |||||
Operating Margin % | 29.01 | |||||
Net Margin % | 21.66 | |||||
EBITDA Margin % | 26.47 | |||||
FCF Margin % | 8.06 | |||||
OCF Margin % | 24.34 | |||||
ROE % | 20.26 | |||||
ROA % | 11.33 | |||||
ROIC % | 23.79 | |||||
3-Year ROIIC % | -385.08 | |||||
ROC (Joel Greenblatt) % | 28.14 | |||||
ROCE % | 17.13 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 156.88 | |||||
Forward PE Ratio | 111.3 | |||||
PE Ratio without NRI | 188.38 | |||||
Price-to-Owner-Earnings | 159.05 | |||||
PS Ratio | 13.79 | |||||
PB Ratio | 9.91 | |||||
Price-to-Tangible-Book | 9.94 | |||||
Price-to-Free-Cash-Flow | 152.44 | |||||
Price-to-Operating-Cash-Flow | 54.94 | |||||
EV-to-EBIT | 105.5 | |||||
EV-to-EBITDA | 79.45 | |||||
EV-to-Revenue | 29.74 | |||||
EV-to-FCF | 369.1 | |||||
Price-to-GF-Value | 1.75 | |||||
Price-to-Graham-Number | 5.35 | |||||
| Price-to-Net-Current-Asset-Value | 49.68 | |||||
Earnings Yield (Greenblatt) % | 0.95 | |||||
FCF Yield % | 0.27 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Biocytogen Pharmaceuticals (Beijing) Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 1,699.234 | ||
| EPS (TTM) (Â¥) | 0.855 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 60.78 | ||
| 14-Day ATR (Â¥) | 9.082206 | ||
| 20-Day SMA (Â¥) | 124.029 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (Â¥) | 48.06 - 154.99 | ||
| Shares Outstanding (Mil) | 443.62 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biocytogen Pharmaceuticals (Beijing) Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biocytogen Pharmaceuticals (Beijing) Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Biocytogen Pharmaceuticals (Beijing) Co Ltd Frequently Asked Questions
What is Biocytogen Pharmaceuticals (Beijing) Co Ltd(SHSE:688796)'s stock price today?
The current price of SHSE:688796 is ¥134.13. The 52 week high of SHSE:688796 is ¥154.99 and 52 week low is ¥48.06.
When is next earnings date of Biocytogen Pharmaceuticals (Beijing) Co Ltd(SHSE:688796)?
The next earnings date of Biocytogen Pharmaceuticals (Beijing) Co Ltd(SHSE:688796) is .
Does Biocytogen Pharmaceuticals (Beijing) Co Ltd(SHSE:688796) pay dividends? If so, how much?
Biocytogen Pharmaceuticals (Beijing) Co Ltd(SHSE:688796) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Biocytogen Enters into Antibody Agreement with Ona Therapeutics to Develop Antibody-Drug Conjugates Targeting Solid Tumors | 2023-12-18 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers